Study guide
7.5 Pharmacological Emergency Interventions & Airway Management
National Board Dental Hygiene Examination NBDHE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Head, Neck & Dental Anatomy, Histology & Embryology
1.1 Head & Neck Cranial Nerves, Osteology & Musculature 1.2 Tooth Morphology, Occlusion & Root Anatomy 1.3 Tooth Development, Histology & Embryology 1.4 Oral Physiology, Salivary Gland Function & TMJ Dynamics 1.5 General Pathology, Inflammation & Immunity Concepts
2 Chapter 2: Oral Pathology, Microbiology & Biofilm Ecology
2.1 Oral Mucosal Lesions, Soft Tissue & Salivary Pathology 2.2 Hard Tissue Anomalies, Cysts, Neoplasms & Radiographic Pathology 2.3 Periodontal Pathology, Plaque Biofilm Ecology & Microbiology 2.4 Cariology, Demineralization Mechanics & Fluoride Chemistry 2.5 Systemic Disease Manifestations & Oral Cancer Risk Factors 2.6 Genetic Conditions, Immunopathology & Diagnostic Biopsy Protocols
3 Chapter 3: Dental Pharmacology, Biochemistry & Nutrition
3.1 Autonomic Drugs, Cardiovascular & Respiratory Pharmacology 3.2 Analgesics, Opioids, NSAIDs & Central Nervous System Agents 3.3 Antimicrobial Therapy, Antibiotic Prophylaxis & Antivirals/Antifungals 3.4 Nutritional Biochemistry, Vitamins, Minerals & Dietary Analysis 3.5 Endocrine Pharmacology, Diabetic Care & Bone Metabolism Agents 3.6 Special Population Pharmacotherapeutics & Drug Interactions
4 Chapter 4: Patient Assessment, Risk Evaluation & Radiographic Interpretation
4.1 Health History Review, ASA Physical Status & Medical Risk Assessment 4.2 Comprehensive Extraoral/Intraoral Examination & Soft Tissue Inspection 4.3 Periodontal Assessment, Probing Techniques & Furcation Classification 4.4 Hard Tissue Examination, Caries Detection & Restorative Evaluation 4.5 Dental Radiography Principles, Physics, Technique & Radiation Safety 4.6 Radiographic Interpretation, Normal Landmarks & Pathologic Artifacts
5 Chapter 5: Periodontal Therapy, Instrumentation & Preventive Services
5.1 Periodontal Disease Etiology, Pathogenesis & Host Response 5.2 Non-Surgical Periodontal Therapy (NSPT) & Scaling/Root Planing (SRP) 5.3 Dental Hygiene Instrumentation, Ergonomics & Sharpness Maintenance 5.4 Preventive Oral Health Agents, Dentifrices, Rinses & Remineralization 5.5 Surgical Periodontal Therapy Overview & Maintenance Protocols 5.6 Patient Motivation, Behavioral Change & Oral Hygiene Instruction 5.7 Care Planning for Special Needs, Medically Compromised & Geriatric Patients
6 Chapter 6: Local Anesthesia Administration, Dental Materials & Special Care
6.1 Local Anesthesia Pharmacology, Neurophysiology & Vasoconstrictors 6.2 Injection Techniques, Anatomical Landmarks & Nerve Blocks 6.3 Local Anesthesia Complications, Toxicity & Nitrous Oxide Sedation 6.4 Dental Materials Chemistry, Impression Media & Restorative Auxiliaries 6.5 Pit & Fissure Sealants, Polishers & Biomaterial Biocompatibility 6.6 Orthodontic, Endodontic, Pediatric & Implant Patient Care
7 Chapter 7: Infection Prevention, OSHA/CDC Protocols & Medical Emergencies
7.1 Infection Control Principles, Transmission Pathways & Standard Precautions 7.2 Sterilization Methods, Biological Monitoring & Chemical Disinfection 7.3 OSHA Bloodborne Pathogens Standard, HazCom & Regulatory Compliance 7.4 Medical Emergency Recognition, CPR/AED & Protocol Management 7.5 Pharmacological Emergency Interventions & Airway Management 7.6 Instrument Processing Safety, Waste Management & Post-Exposure Protocols
8 Chapter 8: Community Oral Health, Epidemiology & Evidence-Based Research
8.1 Dental Public Health Principles, Community Assessment & Needs Analysis 8.2 Oral Epidemiology Indices: DMF, GI, PI, CPITN, Debris & Calculus Indices 8.3 Community Water Fluoridation Standards, Cost-Benefit & Public Health Policy 8.4 Evidence-Based Decision Making, Research Design, Control Groups & Sampling 8.5 Biostatistics in Dental Research: Mean, Median, P-values, Sensitivity & Specificity
9 Chapter 9: Integrated Case-Based Scenarios, Patient Cases & Professional Ethics
9.1 Case Scenario 1: Complex Periodontal Patient with Systemic Conditions 9.2 Case Scenario 2: Pediatric & Adolescent Preventive Management 9.3 Case Scenario 3: Medically Compromised & Special Needs Geriatric Patient 9.4 Case Scenario 4: Oral Pathology Identification & Interprofessional Referral 9.5 Professional Ethics, Jurisprudence & Dental Hygiene Practice Acts 9.6 Risk Management, Informed Consent & Interprofessional Collaboration
7.5 Pharmacological Emergency Interventions & Airway Management
Key Takeaways Explain This Topic AI
The emergency drug kit must contain Epinephrine 1:1000 (anaphylaxis), Nitroglycerin sublingual (angina), Diphenhydramine (allergic reactions), Albuterol (bronchospasm), Aspirin 325 mg (MI), Glucose (hypoglycemia), and Naloxone (opioid overdose).
Epinephrine 1:1000 is administered IM into the vastus lateralis at 0.3 mg for adults and 0.15 mg for pediatric patients.
Sublingual Nitroglycerin (0.4 mg) is administered q5min up to a maximum of 3 doses in 15 minutes; it is strictly contraindicated if PDE-5 inhibitors (e.g., sildenafil) were taken within 24–48 hours.
Supplemental oxygen is indicated in almost all medical emergencies EXCEPT hyperventilation.
Oxygen delivery modes include Nasal Cannula (2–6 L/min for mild distress), Non-Rebreather Mask (10–15 L/min for severe distress), and Bag-Valve-Mask (10–15 L/min for apneic patients).
Last updated: July 2026
7.5 Pharmacological Emergency Interventions & Airway Management
Pharmacological intervention during acute medical emergencies requires an intimate knowledge of emergency drug kit components, mechanisms of action, exact clinical dosages, routes of administration, and absolute contraindications. Furthermore, proficiency in supplemental oxygen administration and airway management modalities is a non-negotiable requirement for dental hygiene practice.
The Emergency Drug Kit: Core Essential Medications
Every dental practice must maintain an accessible, regularly inspected emergency drug kit containing critical emergency drugs categorized by essential level.
Emergency Drug Clinical Indication Standard Adult & Pediatric Dosage Route & Anatomical Site Mechanism of Action & Absolute Contraindications
Epinephrine (1:1000) Acute anaphylaxis; severe refractory bronchospasm Adult : 0.3 mg (0.3 mL); Pediatric : 0.15 mg (0.15 mL) IM into vastus lateralis (anterolateral mid-thigh) Alpha-1 vasoconstriction (reverses hypotension/laryngeal edema), Beta-1 cardiac stimulation, Beta-2 bronchodilation. No absolute contraindications in true anaphylaxis
Nitroglycerin Acute angina pectoris; chest pain 0.4 mg tablet or translingual spray; repeat q5min (max 3 doses in 15 min) Sublingual (SL) under tongue Coronary vasodilator; reduces venous return and myocardial oxygen demand. Contraindicated : Systolic BP <90 mmHg, PDE-5 inhibitors (sildenafil/tadalafil) within 24–48 hrs
Diphenhydramine (Benadryl) Mild allergic reactions; adjunct in anaphylaxis Adult : 25–50 mg; Pediatric : 1 mg/kg Oral (PO) or IM (deltoid) Competitive H1 histamine receptor antagonist. Contraindicated : Acute asthma attack, narrow-angle glaucoma
Albuterol Acute bronchospasm; asthma attack 2 puffs (90 mcg/puff); repeat q5–15min via spacer Inhalation (Metered-Dose Inhaler) Selective Beta-2 adrenergic agonist; rapid bronchodilation. Contraindicated : Hypersensitivity, severe tachyarrhythmias
Aspirin Suspected Myocardial Infarction (MI) 162 to 325 mg (chewable baby aspirins or adult tablet) Oral (PO) (chew and swallow) Irreversible COX-1 inhibitor; blocks thromboxane A2 and platelet aggregation. Contraindicated : Active GI bleeding, severe aspirin allergy
Oral Glucose / Carbohydrates Conscious acute hypoglycemia (<70 mg/dL) 15 to 20 grams (glucose gel, juice, or tablets) Oral (PO) (swallow) Rapidly elevates blood glucose concentration. Contraindicated : Unconscious patient (aspiration risk)
Glucagon Unconscious hypoglycemia 1.0 mg (Adult); 0.5 mg (Child <20 kg) IM or Subcutaneous (SQ) Stimulates hepatic glycogenolysis to release glucose into blood. Contraindicated : Pheochromocytoma
Naloxone (Narcan) Suspected opioid overdose (respiratory depression, pinpoint pupils) 4.0 mg single intranasal spray Intranasal (IN) (spray into one nostril) Competitive opioid mu-receptor antagonist; rapidly reverses respiratory depression. Contraindicated : Hypersensitivity
- Critical Emergency Drug Profiles & Protocols
- 1. Epinephrine 1:1000 (1 mg/mL)
Epinephrine is the primary life-saving drug in emergency medicine. It acts rapidly on alpha and beta-adrenergic receptors. In severe anaphylaxis, alpha-1 receptor stimulation causes intense vasoconstriction, elevating blood pressure and reversing laryngeal edema. Beta-2 receptor stimulation Relaxes bronchial smooth muscle, relieving life-threatening bronchospasm.
2. Nitroglycerin Sublingual (0.4 mg)
Administered for chest pain of suspected cardiac origin. The patient must be seated upright. If chest pain is relieved within 3 to 5 minutes, angina is diagnosed. If pain persists, repeat dose every 5 minutes up to a maximum of 3 doses within 15 minutes .
PDE-5 Inhibitor Warning : Administering nitroglycerin to a patient who has taken PDE-5 inhibitors (e.g., sildenafil [Viagra], tadalafil [Cialis] ) within the preceding 24 to 48 hours causes catastrophic, refractory vasodilation resulting in fatal hypotension.
3. Aspirin 325 mg (Antiplatelet Therapy)
Indicated immediately for any patient presenting with symptoms of acute myocardial infarction. The patient must chew the aspirin prior to swallowing to facilitate rapid buccal mucosal absorption.
4. Naloxone (Narcan) Intranasal Spray (4 mg)
Indicated when a patient exhibits signs of opioid toxicity: respiratory depression ( <8–10 breaths/min ), pinpoint pupils (miosis), and unresponsiveness. Administer a single 4 mg spray into one nostril. If no response occurs within 2 to 3 minutes, administer a second dose into the opposite nostril while maintaining CPR.
Supplemental Oxygen Administration & Flow Rates
Oxygen is indicated for almost all medical emergencies (syncope, angina, MI, anaphylaxis, asthma, seizures) EXCEPT hyperventilation syndrome . Patient Assessment ➔ Conscious / Mild Distress ➔ Nasal Cannula (2-6 L/min | 24-44% O2)
- ➔ Conscious / Severe Distress ➔ Non-Rebreather Mask (10-15 L/min | 60-90% O2)
- ➔ Apneic / Non-Breathing ➔ Bag-Valve-Mask (10-15 L/min | 100% O2)
- Oxygen Delivery Modalities
Nasal Cannula :
Flow Rate : 2 to 6 Liters per minute (L/min) .
Oxygen Concentration : Delivers 24% to 44% Fraction of Inspired Oxygen (FiO2).
Clinical Indication : Conscious, spontaneously breathing patient experiencing mild respiratory or cardiovascular distress (e.g., syncope, mild angina, post-seizure recovery).
Non-Rebreather Mask with Reservoir Bag :
Flow Rate : 10 to 15 Liters per minute (L/min) (reservoir bag must be pre-inflated before placing on face).
Oxygen Concentration : Delivers 60% to 90% FiO2.
Clinical Indication : Conscious or spontaneously breathing patient experiencing severe respiratory or cardiovascular distress (e.g., anaphylaxis, acute MI, severe asthma attack, shock).
Bag-Valve-Mask (BVM) Resuscitator :
Flow Rate : 10 to 15 Liters per minute (L/min) attached to 100% O2 source.
Oxygen Concentration : Delivers up to 100% FiO2.
Clinical Indication : Apneic (non-breathing) patient or severely hypoventilating patient requiring positive-pressure ventilation. Deliver 1 breath every 6 seconds (10 breaths/min) for adults with a pulse.